Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
Sponsor: Oxford Biodynamics Inc.
Summary
The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
2000
Start Date
2024-05-14
Completion Date
2027-05-14
Last Updated
2025-03-17
Healthy Volunteers
No
Locations (3)
Eastern Connecticut Hematology and Oncology
Norwich, Connecticut, United States
Cancer Center of Middle Georgia
Dublin, Georgia, United States
Carolina Blood and Cancer Care Associates
Rock Hill, South Carolina, United States